Imu asx

Financial Times Close.

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes an off-the-shelf allogeneic cell therapy CAR T drug Azer-Cel azercabtagene zapreleucel which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia pox virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Financial Times Close. Search the FT Search.

Imu asx

January 19, Bronwyn Allen. Investors are excited over some further news released by the company today. January 17, James Mickleboro. November 28, James Mickleboro. November 10, James Mickleboro. The healthcare stock is roaring higher again on Friday. But what's getting investors excited? November 9, James Mickleboro. November 8, James Mickleboro. November 6, James Mickleboro.

Mission and Values. New minor risk - Profitability Oct Please choose another Invalid password: must not contain more than 3 consecutive identical characters Invalid password: must not contain more than 3 consecutive sequential characters The password cannot contain the user name, given imu asx, or family name, imu asx.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance. Media centre.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance. Actions Add to watchlist Add to portfolio Add an alert.

Imu asx

Key events shows relevant news articles on days with large price movements. Race Oncology Ltd. RAC Immutep Ltd.

Gay ameteur

Refresh Data. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Leadership Team. How do Imugene's earnings and revenue compare to its market cap? Scott Phillips just released his 5 best stocks to buy right now and you could grab the names of these stocks instantly! Transfer of shares for nil consideration. Last Reported Earnings Dec 31, Show more Markets link Markets. Mission and Values. A verification email has been sent. Nov Consensus forecasts updated Mar Mayne Pharma Group Ltd. Dr Russell is also a member of Risk Committee. Previously, she was serving at oncology clinical development company, Genentech a member of the Roche family , as a Senior Clinical Program Lead at the head office in San Francisco.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved.

In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Use our equities screener to discover other potential opportunities. How do Imugene's earnings and revenue compare to its market cap? Peer analysis Key Information. January 19, Bronwyn Allen. Corporate Governance. Trade our derivatives market. Information Services. Scientific Advisory Board. Botanix Pharmaceuticals Ltd. Open 0.